ABCL
AbCellera BiologicsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The earnings update materially improved the near-term thesis versus the prior baseline because ABCL635 showed clean early safety, target engagement, and a monthly-dosing profile, while liquidity remained substantial enough to fund the next clinical milestones. That supports a cautious positive revision to the evidence base even though the stock is still waiting on Phase 2 efficacy.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +5.1.
What can break
ABCL635 still lacks the Phase 2 efficacy data that would more fully validate the pipeline pivot; disappointing Q3 2026 results would likely pressure the shares.
Momentum
94
Value
41
Sentiment
32
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.20 · Bull $7.50 · Bear $3.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $9.20
Why
Momentum94 · Δ7d +5.1
Value41 · Δ7d +0.1
Sentiment32 · Δ7d -16.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
94
34% active weight
Current posture
7d trendFlat
Δ7d
+5.1
Δ21d
+2.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
32
33% active weight
Current posture
7d trendSoftening
Δ7d
-16.7
Δ21d
-12.5
Why this grade
Composite grade B. Momentum 93.5 / Value 41.1 / Sentiment 31.9
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.87B
Beta
0.80
Shares Out
299.34M
P/E (TTM) · Derived
-12.8
P/S (TTM)
29.07
P/FCF (TTM) · Derived
-12.16
Rev YoY
+37.6%
EPS YoY
-10.3%
Gross Margin
-
Op Margin
-739.7%
Net Debt
-$625.61M
Current Ratio
10.10
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology